DexTech Medical AB (DEX.ST)
- Previous Close
5.00 - Open
5.15 - Bid 4.88 x --
- Ask 5.10 x --
- Day's Range
4.88 - 5.15 - 52 Week Range
3.70 - 7.40 - Volume
11,980 - Avg. Volume
7,045 - Market Cap (intraday)
94.278M - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-0.25 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. Its principal product candidate is OsteoDex that has completed phase IIb clinical trial for the treatment of skeletal metastases in castration resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine tumors, and palliative treatment for advanced prostate cancer; and PSMA-binding conjugates for the target-specific treatment of mCRPC that overexpresses prostate specific membrane antigen (PSMA). In addition, the company offers GuaDex (formarly CatDex), a technology platform and a charge-modified dextran molecule with tumor-toxic properties used for medication development. Dextech Medical AB was incorporated in 2004 and is based in Uppsala, Sweden.
www.dextechmedical.comRelated News
Performance Overview: DEX.ST
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DEX.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DEX.ST
Valuation Measures
Market Cap
92.43M
Enterprise Value
70.28M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.86
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-13.11
Financial Highlights
Profitability and Income Statement
Profit Margin
-62.98%
Return on Assets (ttm)
-9.56%
Return on Equity (ttm)
-13.21%
Revenue (ttm)
7.26M
Net Income Avi to Common (ttm)
-4.57M
Diluted EPS (ttm)
-0.25
Balance Sheet and Cash Flow
Total Cash (mrq)
22.15M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-8.44M
Company Insights: DEX.ST
DEX.ST does not have Company Insights